BCL2 and cancer: Moreover, we found that the combination of low-dose BGB-3111 with low-dose BTZ significantly enhanced the anti-cancer effects by increasing the expression of cleaved PARP and caspase-9 and inhibiting Bcl-2 expression and further affecting the NF-κB pathway.